Clinical Pharmacology and Therapeutics 2014-07-01

Patients benefit from genetics-guided coumarin anticoagulant therapy.

A H Maitland-van der Zee, A K Daly, F Kamali, V G Manolopoulous, V G Manolopoulos, T I Verhoef, M Wadelius, A de Boer, M Pirmohamed

Index: Clin. Pharmacol. Ther. 96(1) , 15-7, (2014)

Full Text: HTML

Abstract

Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings.

Related Compounds

Structure Name/CAS No. Articles
Hydroxypropyl Methyl Cellulose Structure Hydroxypropyl Methyl Cellulose
CAS:9004-65-3
acenocoumarol Structure acenocoumarol
CAS:152-72-7
Warfarin Structure Warfarin
CAS:81-81-2